Antiviral Therapy 14:
|
|
- Sophia George
- 6 years ago
- Views:
Transcription
1 Antiviral Therapy 14: Short communication CD4 + T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4 + T-cell counts >200 cells/mm 3 Marguerite Guiguet 1,2 *, Eric Kendjo 1,2, Guislaine Carcelain 3, Sophie Abgrall 4, Murielle Mary-Krause 1,2, Pierre Tattevin 5, Yazdan Yazdanpanah 6, Dominique Costagliola 1,2 and Xavier Duval 7 on behalf of the FHDH-ANRS CO4 Epidemiology Group 1 NSERM U943, Paris, France 2 Université Pierre et Marie Curie-Paris 6, UMR S943, Paris, France 3 AP-HP Hôpital Pitié-Salpétrière, Paris, France 4 AP-HP, Hôpital Avicenne, Bobigny, France 5 CHU Pontchaillou, Rennes, France 6 CHU Tourcoing, Tourcoing, France 7 APHP, Hôpital Bichat, Paris, France *Corresponding author: mguiguet@ccde.chups.jussieu.fr A list of all participating members of the FHDH-ANRS CO4 Epidemiology Group can be found in the Additional file Background: The aim of this study was to evaluate the clinical prognostic value of the CD4 + T-cell percentage (%CD4), the CD4 + /CD8 + T-cell ratio or the CD8 + T-cell count, in addition to the CD4 + T-cell count and viral load (VL) in antiretroviral-naive HIV- infected patients with CD4 + T-cell counts >200 cells/ mm 3. Methods: Antiretroviral-naive patients (n=9,740) who were AIDS-free and had a CD4 + T-cell count >200 cells/ mm 3 at their first visit after January 1997 were followed-up until treatment initiation or clinical progression (mean follow- up 17 months and 13,660 person-years). Poisson regression was used for statistical analyses. Results: Progression to AIDS-defining events (ADEs), serious ADEs and death occurred in 228 patients (crude rate 1.69 per 100 person-years), 105 patients (0.77 per 100 person-years) and 67 patients (0.49 per 100 personyears), respectively. Regarding progression to ADE, the data fit was improved when the model also included the %CD4 (Akaike s information criteria [AIC] 2,049) and, to a lesser extent, the CD4 + /CD8 + T-cell ratio (AIC 2,053), in addition to CD4 + T-cell count and VL (AIC 2,056). After adjustment for VL and baseline characteristics, patients with CD4 + T-cell counts of cells/mm 3 and %CD4<15% had an estimated incidence of ADE of 3 per 100 person-years, similar to that in patients with CD4 + T-cell counts of cells/mm 3 and %CD4>15%. The %CD4 was also significantly associated with the risk of serious ADE. By contrast, %CD4, CD4 + /CD8 + T-cell ratio or CD8 + T-cell count had no additional prognostic value for the risk of death. Conclusions: In antiretroviral-naive HIV-infected patients with CD4 + T-cell counts >200 cells/mm 3, the %CD4 was predictive of the risk of clinical progression independently of CD4 + T-cell count and VL. Introduction Before treatment initiation, the CD4 + T-cell count and viral load (VL) are strong predictors of the risk of HIV disease progression [1,2]. Updated guidelines now recommend treatment for asymptomatic patients who have CD4 + T-cell counts <350 cells/mm 3 [3,4]. However, the risk of AIDS is far from negligible among patients with CD4 + T-cell counts >350 cells/mm 3 [5]. In addition, results of the SMART study indicate that the risk of serious non-aids events is high among untreated patients with high CD4 + T-cell counts [6]. The need for therapy in asymptomatic patients with higher CD4 + T-cell counts is controversial [7], and additional biological markers predictive of clinical progression would therefore be useful. Here, we focussed on patients with CD4 + T-cell counts >200 cells/mm 3 as previous studies have shown a benefit of initiating 2009 International Medical Press (print) (online) 451
2 M Guiguet et al. antiretroviral therapy above this threshold [8]. The aim was to determine the possible additional prognostic value of the CD4 + T-cell count divided by total lymphocyte count (CD4 + T-cell percentage [%CD4]), the CD4 + /CD8 + T-cell ratio or the CD8 + T-cell count for clinical progression in antiretroviral-naive AIDS-free patients with CD4 + T-cell counts >200 cells/mm 3, on the basis of the incidence rates of first AIDS-defining events (ADEs), serious ADEs and death. Methods The French Hospital Database on HIV (FHDH) is a large French prospective hospital cohort in which enrolment is ongoing [9]. Data from 40 centres in which CD8 + T-cell counts are recorded were analysed here. Patients were eligible if they were antiretroviral-naive, AIDSfree and had CD4 + T-cell counts >200 cells/mm 3 at their first visit after January The patients were monitored from this first visit until the first clinical event, death or last visit. Patients were censored when their CD4 + T-cell count decreased to <200 cells/mm 3 or when they started antiretroviral therapy. The following clinical events were studied: ADEs, serious ADEs (all ADEs except for recurrent bacterial pneumonia, oesophageal candidiasis, herpes simplex virus disease, and pulmonary and extrapulmonary tuberculosis) and death. All biological markers were studied as time-varying factors. Variables were updated at each follow-up and were categorized using the following cutoffs: CD4 + T-cell count ( , , and 650 cells/ mm 3 ), VL (<4, and >5 log 10 copies/ml); %CD4 (<15%, % and 20%), CD4 + /CD8 + T-cell ratio (< and >0.45) and CD8 + T-cell count (<400, and >800 cells/mm 3 ). A Poisson regression model was fitted to evaluate independent contributions of the CD4 + T-cell count, VL, sex, age at the first visit (<50 and 50 years) and the HIV transmission group (injection drug users versus others) to the rate of progression. Rate ratios (RRs) and 95% confidence intervals (CIs) were estimated after adjusting for repeated observations for a given patient. Each additional marker (%CD4, CD4 + /CD8 + T-cell ratio and CD8 + T-cell count) was then introduced. As the different models were not nested, the contribution of each additional covariate was assessed using Akaike s information criterion (AIC), with the lowest AIC value indicating the best fit. Following the empiric rule proposed by Burnham and Anderson [10], we only considered additional covariates that reduced the AIC by 4 compared with the initial model. The risk of progression was estimated in each stratum of CD4 + T-cell counts and %CD4 values after adjusting for VL, sex, age and the HIV transmission group. As Poisson regression and Cox models gave similar results, we also assessed changes in model discrimination when additional marker was included to evaluate the prognostic value of the marker. The ability of Cox models to classify patients according to their risk of clinical progression was assessed by using the C-statistic developed for survival time data with timedependent covariates [11]. Results A total of 9,740 patients who were antiretroviral-naive, AIDS-free and had CD4 + T-cell counts >200 cells/mm 3 at their first visit after January 1997 were followed-up within the FHDH cohort until treatment initiation or clinical progression, yielding a mean of 17 months (±sd 21.5) and 13,660 person-years. Table 1 shows the patients baseline data. Median age was 35 years and 10% of patients were >50 years of age; 63% of patients were male and 11% were injection drug users. At enrolment, 68% of patients had CD4 + T-cell counts >350 cells/mm 3 and CD4 + T-cell counts were >350 cells/ mm 3 during 78% of the total person-years of follow-up. HIV RNA levels were >5 log 10 copies/ml in 17% of patients at baseline, and remained above this level during 10% of person-years of follow-up. At baseline, the %CD4 was <15% in 14% of patients, the CD4 + /CD8 + T-cell ratio was <0.30 in 22% of patients and 37% of patients had CD8 + T-cell counts <800 cells/mm 3. Progression to ADEs, serious ADEs and death occurred in 228 patients (crude rate 1.69 per 100 person- years), 105 patients (crude rate 0.77 per 100 person-years) and 67 patients (crude rate 0.49 per 100 person-years), respectively. The most frequent events were tuberculosis (n=89), Kaposi s sarcoma (n=34), non-hodgkin lymphoma (n=24), oesophageal candidiasis (n=19), recurrent bacterial pneumonia (n=17) and Pneumocystis jirovecii pneumonia (n=14). As expected, the CD4 + T-cell count and VL were strong predictors of clinical progression, and patients with high VL were 2 as likely to die (Table 2). Patients >50 years of age were at an increased risk of all three events, and men were more at risk than women of serious ADE and death. HIV infection by injection drug use was not associated with more rapid progression to ADE or serious ADE, but it was associated with an increased risk of death. Compared with the initial model of the rate of progression to ADE, which included CD4 + T-cell count, VL, sex, age and the HIV transmission group (AIC 2,056), the data fit was improved when the model also included the %CD4 (AIC 2,049), and to a far lesser extend the CD4 + /CD8 + T-cell ratio (AIC 2,053) or the CD8 + T-cell count (AIC 2,057). Discrimination was slightly improved when the %CD4 was included in the model for the prediction of clinical progression. The C-statistics for models of ADE were (with CD4 + T-cell count, VL, sex, age and transmission group International Medical Press
3 CD4 + T-cell percentage predicts progression in ART-naive patients as predictors) and (with CD4 + T-cell count, VL, sex, age, transmission group and %CD4 as predictors). Compared with patients with %CD4>20%, the risk of clinical progression was higher in patients with values in the range of 15 20% (RR 1.5, 95% CI ), and patients with values <15% (RR 2.0; 95% CI ). The %CD4 was also significantly associated with the risk of serious ADEs. The C-statistics for the two models of serious ADEs were (with CD4 + T-cell count, VL, sex, age and transmission group as predictors) and (with CD4 + T-cell count, VL, sex, age, transmission group and %CD4 as predictors). The %CD4, the CD4 + /CD8 + T-cell ratio, or the CD8 + T-cell count had no additional predictive value for the risk of death. The incidence rates of ADEs and serious ADEs were then estimated within each CD4 + T-cell count stratum according to %CD4, after adjustment for VL, sex, age and the HIV transmission group. As shown in Figure 1, patients with CD4 + T-cell counts between 350 and 500 cells/mm 3 and %CD4<15% had Table 1. Characteristics of AIDS-free antiretroviral-naive patients at study entry and during follow-up from 1997 to 2006 Characteristic Value (n=9,740) Follow-up, person-years (n=13,660) Male, n (%) 6,090 (63) Age years, n (%) 2,729 (28) years, n (%) 4,169 (43) years, n (%) 1,864 (19) 50 years, n (%) 978 (10) Median age, years (IQR) 34 (29 41) Risk factor for transmission Men having sex with men, n (%) 2,725 (28) Injection drug use, n (%) 1,068 (11) Heterosexual contact, n (%) 4,761 (49) Other, n (%) 1,228 (12) CD4 + T-cell count 650 cells/mm 3, n (%) 1,801 (18) 3,176 (23) cells/mm 3, n (%) 168 (19) 3,062 (44) cells/mm 3, n (%) 2,930 (30) 4,341 (32) cells/mm 3, n (%) 3,141 (32) 3,030 (22) Median CD4 + T-cell count, cells/mm 3 (IQR) 431 ( ) 446 ( ) a HIV RNA <4 log 10 copies/ml, n (%) 2,709 (28) 5,250 (38) log 10 copies/ml, n (%) 4,003 (41) 5,493 (40) >5 log 10 copies/ml, n (%) 1,624 (17) 1,310 (10) Missing, n (%) 1,404 (14) 1,606 (12) Median HIV RNA, log 10 copies/ml (IQR) 4.3 ( ) 4.2 ( ) a CD4 + T-cell percentage 20%, n (%) 6,166 (63) 9,054 (66) %, n (%) 1,832 (19) 2,364 (17) <15%, n (%) 1,338 (14) 1,358 (10) Missing, n (%) 404 (4) 884 (7) Median CD4 + T-cell percentage (IQR) 23 (18 30) 24 (18 30) a CD4 + /CD8 + T-cell ratio >0.45, n (%) 5,200 (53) 7,519 (55) , n (%) 2,369 (24) 3,305 (24) <0.30, n (%) 2,154 (22) 2,305 (17) Missing, n (%) 17 (0.2) 531 (4) Median CD4 + /CD8 + T-cell ratio (IQR) 0.47 ( ) 0.48 ( ) a CD8 + T-cell count >800 cells/mm 3, n (%) 6,163 (63) 8,686 (63) cells/mm 3, n (%) 3,165 (32) 4,054 (30) <400 cells/mm 3, n (%) 396 (4) 390 (3) Missing, n (%) 16 (0.2) 530 (4) Median CD8 + T-cell count, cells/mm 3 (IQR) 941 (677 1,309) 954 (692 1,323) a a Median of all measurements during follow-up. IQR, interquartile range. Antiviral Therapy
4 M Guiguet et al. an estimated ADE incidence of 3.5 per 100 personyears, similar to the incidence in patients with CD4 + T-cell counts cells/mm 3 and %CD4>20%. The incidence was between 2 and 3 per 100 personyears in patients with CD4 + T-cell counts of cells/mm 3 and %CD4<15%, and also in patients with CD4 + T-cell counts of cells/mm 3 and %CD %, whereas patients with CD4 + T-cell counts >650 cells/mm 3 and patients with CD4 + T-cell counts of cells/mm 3 and %CD4>20%, had an estimated annual incidence of ADEs of <2 per 100 person-years. Similar trends were observed for serious ADEs. Several sensitivity analyses were conducted, after restricting the study population to patients with CD4 + T-cell counts of cells/mm 3 or >350 cells/mm 3 as recent guidelines recommend treatment for asymptomatic patients with CD4 + T-cell counts below this threshold. We also pooled patients with CD4 + T-cell counts of cells/mm 3 and >650 cells/mm 3 as patients with values >650 cells/mm 3 and %CD4<20% were uncommon (1.4% of person-years). The same model that included the %CD4 in addition to the CD4 + T-cell count and VL was selected for all analyses and similar levels of risk were observed across strata defined by the CD4 + T-cell count and %CD4 (data not shown). The results were also similar after excluding the 27 patients with CD4 + T-cell count >1,500 cells/ mm 3 or after censoring patients with intervals longer than 12 months between two visits. Discussion Among antiretroviral-naive AIDS-free patients with CD4 + T-cell counts >200 cells/mm 3, the %CD4 was associated with clinical progression to AIDS independently of the CD4 + T-cell count, VL, sex, age and the Table 2. Rate ratios based on Poisson regression models indicating the association between covariates and the risk of clinical progression in AIDS-free antiretroviral-naive patients with CD4 + T-cell count >200 cells/mm 3 Model ADE RR (95%CI) P-value Serious ADE RR (95%CI) P-value Death RR (95%CI) P-value Model 1 AIC 2,056 a 1,027 a 659 a CD4 + T-cell count 650 cells/mm < cells/mm ( ) 1.27 ( ) 0.38 ( ) cells/mm ( ) 2.30 ( ) 1.20 ( ) cells/mm ( ) 5.25 ( ) 1.48 ( ) Viral load <4 log 10 copies/ml 1.0 < < log 10 copies/ml 1.65 ( ) 1.77 ( ) 0.79 ( ) >5 log 10 copies/ml 4.59 ( ) 6.64 ( ) 2.40 ( ) Age 50 years versus <50 years 2.05 ( ) ( ) ( ) < Male versus female 0.98 ( ) ( ) ( ) 0.13 Injection drug use versus other groups 1.37 ( ) ( ) ( ) Model 2 b AIC 2,049 (-7) a 1,023 (-4) a 662 (3) a CD4 + T-cell percentage 20% % 1.46 ( ) 1.65 ( ) 1.65 ( ) <15% 2.04 ( ) 2.43 ( ) 2.43 ( ) Model 3 b AIC 2,053 (-3) a 1,028 (1) a 663 (4) a CD4 + /CD8 + T-cell ratio > ( ) 1.23 ( ) 0.95 ( ) < ( ) 1.66 ( ) 0.69 ( ) Model 4 b AIC 2,057 (1) a 1,029 (2) a 661 (2) a CD8 + T-cell count >800 cells/mm cells/mm ( ) 0.67 ( ) 1.08 ( ) <400 cells/mm ( ) 1.08 ( ) 2.15 ( ) a Value is Akaike s information criteria (AIC) score (difference from Model 1). b Model adjusted for current CD4 + T-cell count, viral load, age, sex and HIV transmission group. ADE, AIDS-defining event; CI, confidence interval; RR, rate ratio International Medical Press
5 CD4 + T-cell percentage predicts progression in ART-naive patients HIV transmission group. These results suggest that patients with CD4 + T-cell counts between 350 and 500 cell/mm 3 and %CD4<15% have the same risk of progression, before treatment initiation, as patients with CD4 + T-cell counts between 200 and 350 cells/ mm 3 and %CD4>20%. Guidelines for treatment initiation are currently based mainly on the absolute CD4 + T-cell count. Studies performed before and since the advent of antiretroviral drugs have shown that the CD4 + T-cell count, the %CD4 or the CD4 + /CD8 + T-cell ratio predict the risk of progression to AIDS [12 14]. In a study restricted to patients with CD4 + T-cell counts <350 cells/mm 3, the %CD4 had no supplementary predictive value to the absolute CD4 + T-cell count for progression to AIDS, after adjustment for VL [15]. A longitudinal study performed before the highly active antiretroviral therapy era showed that relatively high baseline CD8 + T-cell counts, which could reflect immunological hyperactivity, were associated with clinical progression, whereas the CD4 + /CD8 + T-cell ratio was less informative [16]. In patients starting antiretroviral therapy, a low %CD4 is consistently associated with disease progression [17 20]. In our study of clinical progression among antiretroviral-naive patients with CD4 + T-cell counts above 200 cells/mm 3, a model including the %CD4 was superior to a model including only the CD4 + T-cell count and VL. The %CD4 made a moderate supplementary contribution to risk prediction Figure 1. Estimated incidence rates of ADEs and serious ADEs A %CD4<15% %CD % %CD4 20% 10.0 ADE rate per 100 person-years B CD4 + T-cell count, cells/mm 3 ADE rate per 100 person-years CD4 + T-cell count, cells/mm 3 (A) AIDS-defining events (ADEs). (B) Serious ADEs. %CD4, CD4 + T-cell percentage. Antiviral Therapy
6 M Guiguet et al. in individual patients, but this simple marker is derived from the CD4 + T-cell count and the total lymphocyte count, both of which are routinely measured during follow-up of HIV-infected patients, and therefore has the advantage of being cost-free. Although biological values are expressed on a continuous scale, we categorized these variables with thresholds that are commonly used in clincial practice and are easier to manipulate. In HIV-infected patients, the CD4 + T-cell count shows within-patient variations that are far from negligible [21,22]. In addition, we performed sensitivity analyses using Cox models that included spline functions of continuous covariables [23]. Models with one knot provided optimal fit. The thresholds were 350 cells/mm 3 and 4 log 10 copies/ml for the CD4 + T-cell count and VL, respectively, in keeping with the results obtained using categorized biological values. On the basis of log-likelihood, both %CD4 and CD8 + T-cell count added prognostic information additionally to CD4 + T-cell and VL when using continuous versions of these predictors. A decreasing risk of clinical progression with increasing %CD4 was observed until the threshold of 20% was reached. The threshold was set at 400 cells/mm 3 for the CD8 + T-cell count, but the risk seemed roughly constant below or above the cutoff point with slopes not significantly different from zero. This study has certain limitations. First, we focused on ADEs, although it would also be interesting to study the predictive value of these additional markers for non-aids events associated with HIV-infection [6,24]. Second, patients were censored at treatment initiation and 62% of patients started treatment before progression to clinical AIDS. To avoid a prescription bias, we also included ADEs and deaths occurring during the first month of therapy, which accounted for 9% of all ADEs and deaths. Our results might not apply to children, pregnant women and patients with specific haematopoietic abnormalities. Information on hepatitis C virus infection and anti-hepatitis C virus therapy that are known to reduce the CD4 + T-cell count were not fully recorded, and we did not therefore analyse this risk factor. In conclusion, this study demonstrates the independent predictive value of %CD4 for the risk of progression to AIDS. This additional marker might assist with the decision on when to begin antiretroviral therapy. Acknowledgements The authors are grateful to all FHDH participants and research assistants, without whom this work would not have been possible. FHDH is supported by Agence Nationale de Recherches sur le SIDA (ANRS), Institut National de la Santé et de la Recherche Médicale (INSERM) and the French Ministry of Health. We thank David Young for his editing help. Disclosure statement The authors declare no competing interests. Additional file An additional file listing participating members of the FHDH-ANRS CO4 Epidemiology Group can be found at References 1. Cascade Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004; 18: Phillips A, Lundgren J. The CD4 lymphocyte count and the risk of clinical progression. Curr Opin HIV AIDS 2006; 1: Clumeck N, Pozniak A, Raffi F, EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents. US Department of Health and Human Services. November 3, 2008 (Updated 3 November Accessed 29 April 2009.) Available from nih.gov/contentfiles/adultandadolescentgl.pdf 5. The UK Collaborative HIV Cohort (CHIC) Study Steering Committee. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS 2007; 21: The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197: Phillips AN, Gazzard BG, Clumeck N, Losso MH, Lundgren JD. When should antiretroviral therapy for HIV be started? BMJ 2007; 334: Lapadula G, Torti C, Maggiolo F, et al. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4 + T-cell counts 200 cells/mm 3. Antivir Ther 2007; 12: Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133: Burnham K, Anderson D. Model selection and inference. A practical information-theoretic approach. New York: Springer-Verlag Kremers WK. Technical report series no 80. Concordance for survival time data: fixed and time-dependent covariates and possible ties in predictor and time. Rochester, MN: Department of Health Sciences Research, Mayo Clinic Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 1989; 2: Pirzada Y, Khuder S, Donabedian H. Predicting AIDSrelated events using CD4 percentage or CD4 absolute counts. AIDS Res Ther 2006; 3: Burcham J, Marmor M, Dubin N, et al. CD4% is the best predictor of development of AIDS in a cohort of HIVinfected homosexual men. AIDS 1991; 5: International Medical Press
7 CD4 + T-cell percentage predicts progression in ART-naive patients 15. Gebo KA, Gallant JE, Keruly JC, Moore RD. Absolute CD4 vs CD4 percentage for predicting the risk of opportunistic illness in HIV infection. J Acquir Immune Defic Syndr 2004; 36: Kvale D, Aukrust P, Osnes K, Muller F, Froland SS. CD4 + and CD8 + lymphocytes and HIV RNA in HIV infection: high baseline counts and in particular rapid decrease of CD8 + lymphocytes predict AIDS. AIDS 1999; 13: Bonnet F, Thiebaut R, Chene G, et al. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy, Aquitaine cohort, France, HIV Med 2005; 6: Hulgan T, Raffanti S, Kheshti A, et al. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active retroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm 3. J Infect Dis 2005; 192: Moore DM, Hogg RS, Yip B, Craib K, Wood E, Montaner JS. CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/µl. HIV Med 2006; 7: Hulgan T, Shepherd BE, Raffanti SP, et al. Absolute count and percentage of CD4 + lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis 2007; 195: Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, Volberding PA. Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoring. J Infect Dis 1994; 169: Stein DS, Korvick JA, Vermund SH. CD4 + lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis 1992; 165: Brenner H, Blettner M. Controlling for continuous confounders in epidemiologic research. Epidemiology 1997; 8: Bonnet F, Chene G, Thiebaut R, et al. Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, HIV Med 2007; 8: Accepted for publication 23 December 2008 Antiviral Therapy
Articles. Funding Agence Nationale de Recherches sur le SIDA et les hépatites (ANRS), INSERM, and the French Ministry of Health.
Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study Marguerite Guiguet, François Boué, Jacques Cadranel,
More informationSupplementary Material*
Supplementary Material* Park LS, Tate JP, Sigel K, Brown ST, Crothers K, Gibert C, et al. Association of Viral Suppression With Lower AIDS-Defining and Non AIDS-Defining Cancer Incidence in HIV-Infected
More informationWhen to start: guidelines comparison
The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count
More informationAntiviral Therapy 2012; 17: (doi: /IMP2093) UPMC Université de Paris 06, UMR_S938, INSERM, CDR Saint-Antoine, Paris, France 2
Antiviral Therapy 2012; 17:915 919 (doi: 10.3851/IMP2093) Short communication Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled
More information9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris. Mark Mascolini
Maintenance With Raltegravir/Etravirine Strong at 48 Weeks in Older Adults - Efficacy of a Maintenance Strategy with Raltegravir/Etravirine : the ANRS 163 ETRAL trial 9th IAS Conference on HIV Science
More informationThe importance of cohort collaborations for guiding clinical management of individuals with HIV infection
The importance of cohort collaborations for guiding clinical management of individuals with HIV infection Caroline Sabin Professor of Medical Statistics and Epidemiology Royal Free and University College
More informationReport Back from CROI 2010
Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco
More informationClinical Progression Rates by CD4 Cell Category Before and After the Initiation of Combination Antiretroviral Therapy (cart)
The Open AIDS Journal, 2008, 2, 3-9 3 Clinical Progression Rates by CD4 Cell Category Before and After the Initiation of Combination Antiretroviral Therapy (cart) Marguerite Guiguet *,1,2, Kholoud Porter
More informationPublished Ahead of Print on October 22, 2012 as /JCO J Clin Oncol by American Society of Clinical Oncology INTRODUCTION
Published Ahead of Print on October 22, 2012 as 10.1200/JCO.2012.44.5486 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2012.44.5486 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R
More informationHAL Id: hal Submitted on 13 Jul 2016
Critical Importance of Long-Term Adherence to Care in HIV Infected Patients in the cart Era: New Insights from Pneumocystis jirovecii Pneumonia Cases over 2004 2011 in the FHDH-ANRS CO4 Cohort Blandine
More informationTable S1. Number of eligible individuals by cohort, HIV-CAUSAL and CNICS Collaborations,
Cohort Table S1. Number of eligible individuals by cohort, HIV-CAUSAL and CNICS Collaborations, 2000-2013 No. of antiretroviraltherapy naïve individuals No. initiated cart regimen in 2000 or later No.
More informationPerformance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination
Lusivika-Nzinga et al. BMC Medical Research Methodology (2017) 17:160 DOI 10.1186/s12874-017-0434-1 RESEARCH ARTICLE Open Access Performance of the marginal structural cox model for estimating individual
More informationHIV/AIDS MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: HIV/AIDS MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN HIV/AIDS MEASURES GROUP: #159. HIV/AIDS: CD4+ Cell Count or CD4+ Percentage Performed #160. HIV/AIDS: Pneumocystis
More informationSpontaneous Control of Viral Replication during Primary HIV Infection: When Is HIV Controller Status Established?
HIV/AIDS BRIEF REPORT Spontaneous Control of Viral Replication during Primary HIV Infection: When Is HIV Controller Status Established? Cécile Goujard, 1,2 Marie-Laure Chaix, 3 Olivier Lambotte, 1,2 Christiane
More informationIncomplete Peripheral CD4 + Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment
MAJOR ARTICLE HIV/AIDS Incomplete Peripheral CD4 + Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment Colleen F. Kelley, 1,a Christina M. R. Kitchen, 2,a Peter
More informationAntiviral Therapy 2015; 20: (doi: /IMP2949)
Antiviral Therapy 2015; 20:655 660 (doi: 10.3851/IMP2949) Short communication Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Grgić I., Židovec Lepej S., Vince A., Begovac J. (2010) Increased frequency of viral loads above 100,000 HIV-1 RNA copies/ml measured by Roche Cobas TaqMan assay in comparison
More informationSupervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis.
Supervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis. J.L. YOZVIAK 1, P. KOUVATSOS 2, R.E. DOERFLER 3, W.C. WOODWARD 3 1 Philadelphia College of Osteopathic
More informationThe Effect of Age on Immune System Reconstitution Among HIV-infected Patients on Antiretroviral Therapy in Resource Limited Settings
The Effect of Age on Immune System Reconstitution Among HIV-infected Patients on Antiretroviral Therapy in Resource Limited Settings Kristen A. Stafford, MPH, PhD, Laurence S. Magder, PhD, Laura L. Hungerford,
More informationUniversity of Bristol - Explore Bristol Research
Trickey, A., May, M. T., Schommers, P., Tate, J., Ingle, S. M., Guest, J. L.,... Sterne, J. A. C. (2017). CD4:CD8 ratio and CD8 count as prognostic markers for mortality in HIV-positive patients on ART:
More informationIncidence of Herpes Zoster in HIV-Infected Adults in the Combined Antiretroviral Therapy Era: Results From the FHDH-ANRS CO4 Cohort
MAJOR ARTICLE HIV/AIDS Incidence of Herpes Zoster in HIV-Infected Adults in the Combined Antiretroviral Therapy Era: Results From the FHDH-ANRS CO4 Cohort Sophie Grabar, 1,2,3,4 Pierre Tattevin, 5 Hana
More informationAppendix NEW METHOD FOR ESTIMATING HIV INCIDENCE AND TIME FROM INFECTION TO DIAGNOSIS USING HIV SURVEILLANCE DATA: RESULTS FOR FRANCE
Supporting document 1 Appendix NEW METHOD FOR ESTIMATING HIV INCIDENCE AND TIME FROM INFECTION TO DIAGNOSIS USING HIV SURVEILLANCE DATA: RESULTS FOR FRANCE Ndawinz JDA 1,2, Costagliola D 1,2,3 and Supervie
More informationOriginal article Duration of first-line antiretroviral therapy in HIVinfected treatment-naive patients in routine practice
Antiviral Therapy 2016; 21:715 724 (doi: 10.3851/IMP3084) Original article Duration of first-line antiretroviral therapy in HIVinfected treatment-naive patients in routine practice Thomas Tesson 1, Mathieu
More informationBHIVA Workshop: When to Start. Dr Chloe Orkin Dr Laura Waters
BHIVA Workshop: When to Start Dr Chloe Orkin Dr Laura Waters Aims To use cases to: Review new BHIVA guidance Explore current data around when to start To discuss: Medical decisions, pros and cons Luigi
More informationPneumococcal pneumonia in HIV-infected patients by antiretroviral therapy periods
DOI: 10.1111/j.1468-1293.2008.00546.x r 2008 British HIV Association HIV Medicine (2008), 9, 203 207 ORIGINAL RESEARCH Pneumococcal pneumonia in HIV-infected patients by antiretroviral therapy periods
More informationIMMunoCoMPEtEnCE. PatIEnts and MEtHods
March 28, 2011 Eu Ro PE an JouR nal of MEd I Cal RE search 101 Eur J Med Res (2011) 16: 101-107 I. Holzapfel Publishers 2011 CanCER RIsk In HIV-InfECtEd IndIVIduals on HaaRt Is largely attributed to oncogenic
More informationTo interrupt or not to interrupt Are we SMART enough?
SMART To interrupt or not to interrupt Are we SMART enough? highly active antiretroviral therapy 5 1996 1997 10 25 43 45 35 metabolism 50 copies/ml lipodystrophy [fat redistribution syndrome] lactic acidosis
More informationHIV Update For the Internist
HIV Update For the Internist Disclosures I declare that I have received no incentives, financial or otherwise, from pharmaceutical or biomedical companies relevant to the content of this talk. As an Infectious
More informationTime to initiation of antiretroviral therapy in HIV-infected patients diagnosed with an opportunistic disease: a cohort study
DOI: 10.1111/hiv.12201 ORIGINAL RESEARCH Time to initiation of antiretroviral therapy in HIV-infected patients diagnosed with an opportunistic disease: a cohort study L Deconinck, 1,2,5 Y Yazdanpanah,
More informationSupplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time.
Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time. Anne Cori* 1, Michael Pickles* 1, Ard van Sighem 2, Luuk Gras 2,
More informationIAS 2013 Towards an HIV Cure Symposium
In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm 3 achieves better HIV-1 reservoirs' depletion and T-cell count restoration IAS 2013 Towards an HIV Cure
More informationThe availability and cost are obstacles to using pvl in monitoring HIV treatment outcomes in resource-constrained settings
Impact of the frequency of plasma viral load monitoring on treatment outcome among perinatally HIVinfected Asian children stable on first-line NNRTI-based cart T Sudjaritruk, DC Boettiger, NV Lam, KAM
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationANRS CO12 CIRVIR - Prospective cohort involving patients with viral cirrhosis B and C
ANRS CO12 CIRVIR - Prospective cohort involving patients with viral cirrhosis B and C Head : Nahon Pierre, Service d'hépatologie, Hôpital Jean Verdier Roudot-thoraval Françoise, Service de santé publique,
More informationFor any cancer and for infection-related cancer, immediate ART was associated with a lower cancer risk in the first three models but not in models D,
Immediate ART in START Cuts Risk of Infection-Linked Cancer About 75% Conference on Retroviruses and Opportunistic Infections (CROI), February 22-25, 2016, Boston Mark Mascolini People who started antiretroviral
More informationThe effect of systemic exposure to efavirenz, sex and age on the risk of virological nonsuppression in HIV-infected African children.
The effect of systemic exposure to efavirenz, sex and age on the risk of virological nonsuppression in HIV-infected African children. Andrzej Bienczak Paolo Denti, Adrian Cook, Veronica Mulenga, Cissy
More informationDefinitions of antiretroviral treatment failure for measuring quality outcomes
DOI: 10.1111/j.1468-1293.2009.00808.x r 2010 British HIV Association HIV Medicine (2010), 11, 427 431 ORIGINAL RESEARCH Definitions of antiretroviral treatment failure for measuring quality outcomes A
More informationClinical Infectious Diseases Advance Access published June 16, Age-Old Questions: When to Start Antiretroviral Therapy and in Whom?
Clinical Infectious Diseases Advance Access published June 16, 2015 1 Age-Old Questions: When to Start Antiretroviral Therapy and in Whom? Rochelle P. Walensky, Martin S. Hirsch From the Division of Infectious
More informationHIV AND LUNG HEALTH. Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital
HIV AND LUNG HEALTH Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital Introduction HIV infection exerts multiple effects on pulmonary immune responses: Generalised state of immune
More informationAntiretroviral Therapy Cohort Collaboration
Antiretroviral Therapy Cohort Collaboration http://www.bristol.ac.uk/art-cc/research/presentations/ 2015 22nd Conference on Retroviruses and Opportunistic Infections, Seattle, USA, February 2015 Margaret
More informationThe Danish HIV Cohort Study, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark 4
Antiviral Therapy 2009 14: 995 1000 (doi: 10.3851/IMP1412) Original article The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish
More informationJournal of Antimicrobial Chemotherapy Advance Access published December 30, 2005
Journal of Antimicrobial Chemotherapy Advance Access published December 30, 2005 Journal of Antimicrobial Chemotherapy doi:10.1093/jac/dki472 Safety and factors predicting the duration of first and second
More informationThe monitoring of HIV-infected patients is based on
AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 32, Number 6, 2016 ª Mary Ann Liebert, Inc. DOI: 10.1089/aid.2015.0348 Prognostic Value of HIV-1 RNA on CD4 Trajectories and Disease Progression Among Antiretroviral-Naive
More informationMDR HIV and Total Therapeutic Failure. Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007
MDR HIV and Total Therapeutic Failure Douglas G. Fish, MD Albany Medical College Albany, New York Cali, Colombia March 30, 2007 Objectives Case study Definitions Fitness Pathogenesis of resistant virus
More informationLê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group
Lê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group 1 AP-HP, Hopital Bichat, Pharmacology-Toxicology, Paris, France, 2 IAME, UMR 1137,
More informationNIH Public Access Author Manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2012 September 1.
NIH Public Access Author Manuscript Published in final edited form as: J Acquir Immune Defic Syndr. 2011 September 1; 58(1): 72 79. doi:10.1097/qai.0b013e318225ba62. CD4 CELL RESPONSES TO COMBINATION ANTIRETROVIRAL
More informationFrequency, determinants and consequences of delayed access to care for HIV infection in France
Antiviral Therapy 12:89 96 Frequency, determinants and consequences of delayed access to care for HIV infection in France Emilie Lanoy 1,2, Murielle Mary-Krause 1,2, Pierre Tattevin 3, Isabelle Perbost
More informationNHS England. Evidence review: Immediate initiation of Anti-Retroviral-Therapy
NHS England Evidence review: Immediate initiation of Anti-Retroviral-Therapy 1 NHS England Evidence review: Immediate initiation of anti-retroviral therapy First published: October 2016 Updated: Not applicable
More informationRisk factors for active tuberculosis following antiretroviral treatment initiation in Abidjan
Risk factors for active tuberculosis following antiretroviral treatment initiation in Abidjan Catherine Seyler, Siaka Toure, Eugène Messou, Dominique Bonard, Delphine Gabillard, Xavier Anglaret Online
More informationINTEGRATING HIV INTO PRIMARY CARE
INTEGRATING HIV INTO PRIMARY CARE ADELERO ADEBAJO, MD, MPH, AAHIVS, FACP NO DISCLOSURE 1.2 million people in the United States are living with HIV infection and 1 in 5 are unaware of their infection.
More informationOriginal Article. Noparat Oniem, M.D., Somnuek Sungkanuparph, M.D.
Original Article Vol. 29 No. 1 Primary prophylaxis for cryptococcosis with fluconazole:- Oniem N & Sungkanuparph S. 5 Primary prophylaxis for cryptococcosis with fluconazole among HIV-infected patients
More informationTetiana Kyrychenko MD. Poltava Regional HIV/AIDS Prevention and Control Center. 4TH CEE MEETING ON VIRAL HEPATITIS AND HIV October 2018, Prague
Tetiana Kyrychenko MD Poltava Regional HIV/AIDS Prevention and Control Center 4TH CEE MEETING ON VIRAL HEPATITIS AND HIV 11-12 October 2018, Prague tanakyrychenko@gmail.com Disclosures No relevant conflicts
More informationFertility Desires/Management of Serodiscordant HIV + Couples
Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University
More informationPredicting mortality in HIV-infected children initiating highly active antiretroviral therapy: A risk scoring system for resource-limited settings
Predicting mortality in HIV-infected children initiating highly active antiretroviral therapy: A risk scoring system for resource-limited settings By James Nugent A Master s Paper submitted to the faculty
More informationStudy explores risk for shingles in the current era
CATIE-News CATIE s bite-sized HIV and hepatitis C news bulletins. Study explores risk for shingles in the current era 19 February 2015 Infection with VZV (varicella zoster virus), a member of the herpes
More informationSupplementary Material. In this supplement we derive the full form of the monetary and health costs of testing
Supporting document Supplementary Material In this supplement we derive the full form of the monetary and health costs of testing every years, and ; we derive the approximation shown in (1); and we justify
More informationEffect of HAART on growth parameters and absolute CD4 count among HIV-infected children in a rural community of central Nigeria
Niger J Paed 2014; 41 (1): 1-6 Ebonyi AO Oguche S Dablets E Sumi B Yakubu E Sagay AS ORIGINAL Effect of HAART on growth parameters and absolute CD4 count among HIV-infected children in a rural community
More informationCryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease
Cryptococcosis of the Central Nervous System: Classical and Immune-Reconstitution Disease Assist Prof. Somnuek Sungkanuparph Division of Infectious Diseases Faculty of Medicine Ramathibodi Hospital Mahidol
More informationTechnical appendix to How should access to antiretroviral treatment be measured? Published in the Bulletin of the World Health Organization
Technical appendix to How should access to antiretroviral treatment be measured? Published in the Bulletin of the World Health Organization Leigh F. Johnson Andrew Boulle Centre for Infectious Disease
More informationHIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
More informationCLINICAL AND EPIDEMIOLOGICAL STUDY. Infection DOI /s Received: 28 June 2010 / Accepted: 30 November 2010 Ó Urban & Vogel 2010
Infection DOI 10.1007/s15010-010-0070-8 CLINICAL AND EPIDEMIOLOGICAL STUDY Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of
More informationDeterminants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus
Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus Leah Burke, M.D. 1, Daniel Fierer, M.D. 2, David Cassagnol,
More informationMeasure #161: HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy
Measure #161: HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy 2012 PHYSICIAN QUALITY REPTING OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION:
More information1950 CID 2009:49 (15 December) HIV/AIDS. Received 17 April 2009; accepted 31 July 2009; electronically published 13 November 2009.
HIV/AIDS BRIEF REPORT Long-Term Evolution and Determinants of Renal Function in HIV-Infected Patients Who Began Receiving Combination Antiretroviral Therapy in 1997 1999, ANRS CO8 APROCO-COPILOTE Catherine
More informationEuropean Guidelines. for the Clinical Management and Treatment of HIV Infected Adults
European Guidelines for the Clinical Management and Treatment of HIV Infected Adults 2005 These Euroguidelines result from the comparison of guidelines from several European countries and from a discussion
More informationMortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord
Mortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord Laurence WEISS Hôpital Européen Georges Pompidou, Université Paris-Descartes Paris, France Deaths per 100 Person-Years
More informationJMSCR Vol 3 Issue 10 Page October 2015
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x DOI: http://dx.doi.org/10.18535/jmscr/v3i10.20 Drugs Related Changes of Haemoglobin and CD4 Counts in HIV-Infected Patients on Antiretroviral
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More information1. PICO question. Interventions Reference standard or comparators Outcomes. Study design Other
Title: Strategies for optimizing HIV monitoring among adults, children and pregnant women living with HIV receiving antiretroviral therapy: a systematic review Contents 1. PICO question... 1 2. Search
More informationSECONDARY OBJECTIVES:
Study No.: 112 419 Title: Retrospective study using the NADIS database of the reasons for discontinuing the Abacavir-Lamivudine combination in HIV-infected patients treated by an antiretroviral regimen
More informationAccepted Manuscript. Letter to the Editor. Reply to: From the CUPIC study: Great times are not coming (?)
Accepted Manuscript Letter to the Editor Reply to: From the CUPIC study: Great times are not coming (?) Christophe Hezode, Helene Fontaine, Yoann Barthe, Fabrice Carrat, Jean-Pierre Bronowicki PII: S0-()00-
More informationHIV treatment interruptions are associated with heightened biomarkers of inflammation, coagulopathy and T-cell activation despite viral suppression
HIV treatment interruptions are associated with heightened biomarkers of inflammation, coagulopathy and T-cell activation despite viral suppression Nicholas Musinguzi on behalf of Jose Castillo-Mancila,
More informationAssociation of Cigarette Smoking With HIV Prognosis Among Women in the HAART Era: A Report From the Women s Interagency HIV Study
Association of Cigarette Smoking With HIV Prognosis Among Women in the HAART Era: A Report From the Women s Interagency HIV Study Joseph G. Feldman, DrPH, Howard Minkoff, MD, Michael F. Schneider, MS,
More information3rd IAS Conference on HIV Pathogenesis and Treatment. Poster Number Abstract #
3rd IAS Conference on HIV Pathogenesis and Treatment 24 27 July 2005, Rio de Janeiro, Brazil Poster Number Abstract # TuFo0106 TuFo0106 Characterization of Anemia in HIV-infected (HIV+) Subjects Treated
More informationEstimating the proportion of patients infected with HIV who will die of comorbid diseases
The American Journal of Medicine (2005) 118, 890-898 CLINICAL RESEARCH STUDY Estimating the proportion of patients infected with HIV who will die of comorbid diseases R. Scott Braithwaite, MD, a Amy C.
More informationInitiation of antiretrovirals in HIV/HCV co-infected MSM: Are we too late?
Initiation of antiretrovirals in HIV/HCV co-infected MSM: Are we too late? Thomas Martin, Sophie Jose, Alicia Thornton, Natasha Martin, Caroline Sabin, Mark Nelson Background Antiretroviral therapy (ART)
More informationDownloaded from:
Iwuji, CC; Churchill, D; Gilleece, Y; Weiss, HA; Fisher, M (2013) Older HIV-infected individuals present late and have a higher mortality: Brighton, UK cohort study. Bmc Public Health, 13. ISSN 1471-2458
More informationAntiviral Therapy 2016; 21: (doi: /IMP3052)
Antiviral Therapy 2016; 21:725 730 (doi: 10.3851/IMP3052) Short communication HIV viral suppression in TREAT Asia HIV Observational Database enrolled adults on antiretroviral therapy at the Social Health
More informationHIV-HBV coinfection in HIV population horizontally infected in early childhood between
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE HIV-HBV coinfection in HIV population horizontally infected in early childhood between 1987-1990 Supervising professor: Prof. Cupşa Augustin
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNo variability across centers in adherence and response to HAART in French hospitals: results from the ANRS-EN12-VESPA study
No variability across centers in adherence and response to HAART in French hospitals: results from the ANRS-EN12-VESPA study 1 * Rémi Sitta, France Lert 1, Alice Gueguen 1, Bruno Spire 2, Rosemary Dray-Spira
More informationMortality Rates Among People With HIV, Long on the Wane, Continue to Drop HIV Medicine Feb 2013
John F. White III, MD, MBA, FLMI VP and Medical Director American National Insurance Company 1 Mortality Rates Among People With HIV, Long on the Wane, Continue to Drop HIV Medicine Feb 2013 2 1 3 My Opinions
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More information1. Africa Centre for Health and Population Studies 2. London School of Hygiene and Tropical Medicine 3. University College London
A systematic review of the effects of interrupted antiretroviral interventions for prevention of mother-to-child transmission of HIV on maternal disease progression and survival Naidu KK 1, Mori R 2, Newell
More informationPharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women
Pharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women DR MINH LÊ PHARMACO-TOXICOLOGY DEPARTMENT APHP, HÔPITAL BICHAT-CLAUDE BERNARD PARIS, FRANCE ABSTRACT #O_01 17TH INTERNATIONAL
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION C-Reactive Protein Is a Marker for Human Immunodeficiency Virus Disease Progression Bryan Lau, PhD, MHS, ScM; A. Richey Sharrett, MD, DrPH; Larry A. Kingsley, DrPH; Wendy Post, MD,
More informationTools to Monitor HIV Infection in 2013 and Beyond.
Tools to Monitor HIV Infection in 2013 and Beyond. Federico García, fegarcia@ugr.es Servicio de Microbiología Univ. Hospital San Cecilio Granada, Spain Outline Address clinical questions: Ultra sensitive
More informationAntiretroviral Therapy in HIV and Hepatitis Coinfection: What Do We Need to Consider?
Antiretroviral Therapy in HIV and Hepatitis Coinfection: What Do We Need to Consider? Saturday 22nd March 2014, Mumbai, India Jürgen K. Rockstroh Department of Internal Medicine I University Hospital Bonn,
More informationQ and A - the PARTNER Study: new results from PARTNER 2
Q and A - the PARTNER Study: new results from PARTNER 2 1. Study results What is the PARTNER Study? The PARTNER study is an international two-phase study that looked at whether HIV transmission occurs
More informationHighly active antiretroviral (ARV) therapy (HAART) has dramatically
ORIGINAL STUDIES Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral
More informationCancer risk and prevention in persons living with HIV/AIDS (PLWHA) Robert Dubrow, MD, PhD Professor of Epidemiology Yale School of Public Health
Cancer risk and prevention in persons living with HIV/AIDS (PLWHA) Robert Dubrow, MD, PhD Professor of Epidemiology Yale School of Public Health Main collaborators Lesley Park Janet Tate Amy Justice Michael
More informationCan we treat our way out of the HIV epidemic?
Can we treat our way out of the HIV epidemic? Richard E. Chaisson, MD Center for AIDS Research Center for TB Research Johns Hopkins University Schoolboy s (and politician s) tricks for evading the question
More informationTitle: Revision of the Surveillance Case Definition for HIV Infection and AIDS Among children age > 18 months but < 13 years
06-ID-02 Committee: Infectious Disease Title: Revision of the Surveillance Case Definition for HIV Infection and AIDS Among children age > 18 months but < 13 years Statement of problem: Advances in HIV
More informationDecline of CD3-positive T-cell counts by 6 months of age is associated with rapid disease progression in HIV-1 infected infants
Decline of CD3-positive T-cell counts by 6 months of age is associated with rapid disease progression in HIV-1 infected infants Javier Chinen, Baylor College of Medicine Kirk Easley, Emory University Herman
More informationNatural history of HIV Infection
HIV in Primary Care Joint RCGP/BHIVA Multidisciplinary Conference Dr Ian Williams University College London Medical School Friday 25 January 2013, Royal College of General Practitioners, London HIV Treatment
More informationComparison of CD4+ T-Cell Changes In Response To Highly Active Antiviral. Therapy (HAART) In Adolescents And Children Enrolled At Parirenyatwa
Comparison of CD4+ T-Cell Changes In Response To Highly Active Antiviral Therapy (HAART) In Adolescents And Children Enrolled At Parirenyatwa Hospital Family Care Centre (2005-2010) - Secondary Data Analysis
More informationIJC International Journal of Cancer
IJC International Journal of Cancer Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort Mira Hleyhel 1,2, Aurelien Belot
More informationORIGINAL INVESTIGATION. National Quality Forum Performance Measures for HIV/AIDS Care
ORIGINAL INVESTIGATION HEALTH CARE REFORM National Quality Forum Performance Measures for HIV/AIDS Care The Department of Veterans Affairs Experience Lisa I. Backus, MD, PhD; Derek B. Boothroyd, PhD; Barbara
More informationClinical Case. Prof.ssa Cristina Mussini
Clinical Case Prof.ssa Cristina Mussini Clinical history Male, born in Ivory Coast in 1968. HIV positive since dal 1998 Risk factor: heterosexual contacts He started antiretroviral therapy in 2001 with
More informationImprovement in the Health of HIV-Infected Persons in Care: Reducing Disparities
HIV/AIDS MAJOR ARTICLE Improvement in the Health of HIV-Infected Persons in Care: Reducing Disparities Richard D. Moore, Jeanne C. Keruly, and John G. Bartlett Department of Medicine, Johns Hopkins University
More information